ADC Therapeutics CFO Jenn Creel to depart, Jose Carmona to succeed

ADC Therapeutics (ADCT) announced the appointment of Jose Carmona as CFO, effective December 19. He will serve on the company’s executive leadership team and succeeds Jenn Creel, who is leaving to pursue other opportunities. Carmona is a seasoned CFO with over 20 years of leadership, commercial and partnership experience in the pharmaceutical industry, both in the U.S. and internationally. He most recently served as CFO of Rubius Therapeutics (RUBY) where he was responsible for all financial functions as well as business development, investor relations, information technology and procurement.